Report of the overall diagnostic yield of GeneDx’s first 3,040 exome cases (28.8%). This study identified that analysis of trios significantly improves diagnostic yield compared to proband-only testing for genetically heterogeneous disorders.
To ensure that a patient’s test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at support@genedx.com to determine how to proceed.
Report of the overall diagnostic yield of GeneDx’s first 3,040 exome cases (28.8%). This study identified that analysis of trios significantly improves diagnostic yield compared to proband-only testing for genetically heterogeneous disorders.